Background: Acute pharyngotonsillitis (APT) is one of the most common inflammatory processes of adults and children in an outpatient setting. Increasing failure rates, hypersensitivity to penicillin, the required multiple daily doses and common side effects lead to poor patients compliance and thus inadequate treatment duration, providing therefore ground for considering alternative antimicrobial agents.
Material And Methods: This multicenter, randomized, single blind study was undertaken in order to compare efficacy and safety of cefaclor (375 mg BID) and amoxicillin/clavulanate (625 mg BID) in 10 days treatment regiment of ambulatory patients with APT. A total of 200 patients (age range between 12-65 years) with symptoms of APT and positive antigen strep test were enrolled into the study. Clinical and bacteriological responses were assessed after the end of treatment (14th-18th day) and at the follow-up visit (38th-45th day). All GABHS strains, isolated from throat cultures, were tested for in vitro sensitivity to the antibiotics used in the study and no strain was found resistant to both antibiotics.
Results: The results indicated that both antibiotics had high--almost 99% effectiveness at the post therapy visit. On the follow up visit an increased tendency of relapses was observed in the amoxicillin/clavulanate treated group, compared to cefaclor treated group (8.33% vs 3.29%). Relative risk of relapse in patients treated with amoxicillin/clavulanate was 2.6 greater compared to cefaclor. There were significantly higher rates of gastrointestinal adverse events in group treated with amoxicillin/clavulanate (29/97 patients; 29.89%) compared to cefaclor (16/95 patients; 16.84%) - p< 0.03. Frequency of other adverse events did not differ significantly between the groups.
Conclusions: Cefaclor and amoxicillin/clavulonate provide a clinically and bacteriologically effective treatment for patients with pharyngotonsillitis caused by GABHS, but cefaclor treatment is significantly safer in regard to gastrointestinal side effects.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Monitoring and controlling bacteria in cleanrooms of pharmaceutical plant model: an in vitro study.
Environ Monit Assess
December 2024
Department of Botany and Microbiology, Faculty of Science, Al-Azhar University, Cairo, Egypt.
Article Synopsis
- The study investigates bacterial species in a new pharmaceutical facility in 6th of October City, Egypt, focusing on their resistance patterns and phylogenetic relationships.
- All bacterial isolates were sensitive to Levofloxacin, but five Gram-positive and one Gram-negative multidrug-resistant strains were identified, raising concerns about potential contamination in drug manufacturing.
- Disinfectants tested were mostly effective, with Clorox showing the best results against biofilms, while Dettol was less effective and only bacteriostatic, indicating the need for careful selection of disinfectants in cleanroom environments.
Exploring the Therapeutic Potential of High Dose Co-amoxiclav (1 gm) in Different Clinical Conditions: A Review.
Cureus
July 2024
Medical Affairs, Alkem Laboratories Ltd., Mumbai, IND.
Article Synopsis
- - Amoxicillin/clavulanate (co-amoxiclav) is a commonly used antibiotic effective against certain resistant bacteria, but there's a lack of solid data supporting current dosing guidelines.
- - A review of literature from 1992 to 2024 focused on the high-dose co-amoxiclav (875 mg/125 mg) and found it effective for various infections like pneumonia and sinusitis, often performing as well or better than other antibiotics.
- - Co-amoxiclav (875 mg/125 mg) is generally well-tolerated, primarily causing mild gastrointestinal side effects, and its optimized dosing helps improve treatment outcomes in the face of rising antibiotic resistance.
Application of Cefaclor in Orthodontics through Micro-Implant Anchorage in Patients with Periodontitis.
Ann Ital Chir
June 2024
Department of Stomatology, First People's Hospital of Yongkang City, 321300 Yongkang, Zhejiang, China.
Aim: Chronic periodontitis leads to gingival swelling, hyperplasia, and tooth mobility, which affects orthodontic treatment. The aim of this study was to investigate the application of cefaclor in orthodontics through micro-implant anchorage in patients with periodontitis.
Methods: A retrospective study was conducted on patients with periodontitis who received micro-implant anchorage treatment in the department of orthodontics at the First People's Hospital of Yongkang City from July 2019 to January 2022.
Impact of the COVID-19 pandemic on Haemophilus influenzae infections in pediatric patients hospitalized with community acquired pneumonia.
Sci Rep
June 2024
Department of General Practice, Yongchuan Hospital of Chongqing Medical University, No. 439, Xuanhua Street, Chongqing, 402160, China.
The COVID-19 pandemic has altered the infection landscape for many pathogens. This retrospective study aimed to compare Haemophilus influenzae (H. influenzae) infections in pediatric CAP patients hospitalized before (2018-2019) and during (2020-2022) the COVID-19 pandemic.
View Article and Find Full Text PDFAntiurease Activity of Antibiotics: In Vitro, In Silico, Structure Activity Relationship, and MD Simulations of Cephalosporins and Fluoroquinolones.
ACS Omega
March 2024
Institute of Chemistry, B.J. Campus, The Islamia University of Bahawalpur, Bahawalpur 36000, Pakistan.
infection is widespread in 50% of the world's population and is associated with gastric ulcers and related disorders that ultimately culminate in gastric cancer. Levofloxacin-based, or clarithromycin-based, triple therapy is frequently used to inhibit the bacterial urease enzyme for the eradication of . A comprehensive investigation based on the urease inhibitory profiles of antibiotics and their computational implications is lacking in the scientific literature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!